ARTN Knockout MDA-MB-231 Cell Line

The ARTN Knockout MDA-MB-231 Cell Line is a CRISPR/Cas9-edited human triple-negative breast cancer cell line with targeted disruption of the ARTN gene. ARTN encodes the neurotrophic factor artemin, a key driver of tumor invasion and metastasis. This knockout model enables loss-of-function studies to dissect artemin??s role in breast cancer progression, providing a well-defined system for mechanistic investigation of ARTN-mediated signaling and cellular phenotypes. The cell line is generated via CRISPR/Cas9-mediated gene disruption, ensuring stable elimination of artemin function for rigorous experimental analysis.

The parental MDA-MB-231 cell line is a mesenchymal-like, epithelial TNBC line derived from the pleural effusion of a Caucasian female with metastatic adenocarcinoma. Exhibiting high invasive and metastatic capacity, these cells lack hormone receptor and HER2 expression and are widely employed in EMT and metastasis research. The ARTN knockout variant retains this aggressive background while specifically eliminating artemin function, facilitating direct assessment of ARTN-dependent processes in a clinically relevant context.

Artemin signals primarily through the GFR??3 co-receptor, inducing dimerization and activation of the RET receptor tyrosine kinase. This triggers SRC/FAK, PI3K/AKT, and MAPK/ERK cascades, promoting cell survival, invasion, and EMT. Upstream regulators include estrogen deprivation, androgen signaling, and pro-inflammatory cytokines. Downstream, artemin upregulates MMP-2, MMP-9, the transcription factor SNAI1, and mesenchymal markers vimentin and N-cadherin, all critical for invasive behavior. Artemin also exhibits low-affinity binding to GFR??1, but its primary signaling is mediated through the GFR??3?CRET axis. The resulting SRC/FAK pathway modulates focal adhesion dynamics, while PI3K/AKT and MAPK/ERK drive survival and proliferation, establishing this signaling network as a central driver of malignancy.

In the MDA-MB-231 background, ARTN knockout provides a valuable tool for studying endocrine-resistant breast cancer, bone metastasis, and neuropathic pain mechanisms. Artemin overexpression correlates with enhanced invasiveness and poor prognosis; its loss allows examination of attenuated EMT, reduced metastatic potential, and altered drug sensitivity. This model enables detailed analysis of how neurotrophic factor signaling intersects with the tumor microenvironment and contributes to aggressive cancer phenotypes.

Researchers can utilize this cell line in diverse assays: Western blotting for phosphorylated AKT, ERK, and SNAI1; RT-qPCR for MMP2, SNAI1, and VIM transcripts; Boyden chamber invasion and wound healing migration assays; immunofluorescence for E-cadherin and vimentin; xenograft metastasis models; and tamoxifen sensitivity assays. These approaches facilitate robust investigation of ARTN-dependent signaling, invasion, EMT, and drug resistance. The knockout line is also suitable for co-culture systems exploring tumor-stroma interactions. For technical inquiries, please contact Ascent Research.